Biodesix announces new data on nodify lung® nodule risk assessment testing at the chest 2021 annual meeting

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company, today announced that multiple data presentations will occur at the 2021 annual chest virtual conference. presentations will include newly emerging data from the post-market, prospective, real-world oracle study (an observational registry study to evaluate the performance of the nodify xl2® test - oracle [nct03766958]), demonstrating that incorporation of this blood-based test in t
BDSX Ratings Summary
BDSX Quant Ranking